<i id='06366249A9'><strike id='06366249A9'><tt id='06366249A9'><pre id='06366249A9'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
AltruBio raises $225 million to develop ulcerative colitis drug 
Affirmative action in medical school literally saved lives 
Brain technologies pose threats that are all too real, experts warn 
Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen 
Mass General, Mayo Clinic look to monetize custom 
23andMe had bad news about my health. I wish a person had delivered it 
Sepsis can kill a child within hours. Here's how hospitals are fighting back 
At least 13 dead in Texas as scorching temps continue 
BIO to announce reorganization, senior leaders expected to depart 
United colonoscopy coverage change 'may cost lives,' doctors say 
Brain MRIs reveal impact of 'toxic stress' on Black children 
In Memoriam: Notable people who died in 2023 
How a small hospital in rural Puerto Rico survived Hurricane Maria 
New air purifier tech could be key to improving indoor air quality 
